AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7648804
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg daily
Trial: 15671606
Drug: Tirofiban +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban + Heparin (Group III)
Trial: 15671606
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (Group I)
Trial: 7996404
Drug: Retained anterior
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retained anterior capsule flap
Trial: 24212227
Drug: Recanalization (RC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recanalization (RC) with 20 G endodiathermy bipolar probe connected to a 7 W diathermy followed by bicanalicular intubation
Trial: 21515812
Drug: Oral dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of [D(10)]phenanthrene (10 μg)
Trial: 21515812
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of [D(10)]phenanthrene (10 μg)
Trial: 8383688
Drug: Granisetron 160
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 160 micrograms/kg (additional doses allowed)
Trial: 31957251
Drug: WBI/WBI-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBI/WBI-chemotherapy
Trial: 31184015
Drug: Intravesical sodium
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical sodium hyaluronate 50 ml 1 time per week for 12 weeks
Trial: 31184015
Drug: Intravesical sodium
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical sodium hyaluronate combined with oral chondroitin sulfate 0.39 g (2 capsules 3 times a day) for 12 weeks
Trial: 1814902
Drug: Azoran (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azoran (1000 mg)
Trial: 1814902
Drug: Imuran (imported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imuran (imported formulation)
Trial: 17139602
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with endothelin-receptor inhibitors, phosphodiesterase-5 inhibitors, and prostanoids
Trial: 17139602
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (e.g., Imatinib)
Trial: 14663808
Drug: 4.8% tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8% tranexamic acid mouthwash (10 mL, 4 times a day for 7 days postoperatively)
Trial: 8926685
Drug: Intense preradiation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense preradiation chemotherapy
Trial: 1290924
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg/day for 4 days)
Trial: 6585734
Drug: 3‐mg prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mg prostaglandin E2 vaginal suppository
Trial: 26787238
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone
Trial: 24711779
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of manual and manipulative therapy
Trial: 15827075
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program in a community pharmacy
Trial: 11574338
Drug: Balanced Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Fluid group (Hartmann's solution and 6% hetastarch in balanced electrolyte and glucose injection)
Trial: 11574338
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (0.9% sodium chloride solution and 6% hetastarch in 0.9% sodium chloride solution)
Trial: 9576119
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 or 20 mg BID
Trial: 9576119
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 or 10 mg BID
Trial: 8154647
Drug: Accelerated-dose tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated-dose tissue plasminogen activator (tPA)
Trial: 24252845
Drug: EPA+DHA supplementation
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA supplementation (0, 300, 600, 900, 1800 mg daily)
Trial: 18981939
Drug: GLU +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU + CAF (6.4% glucose plus caffeine providing 5.3 mg kg(‐1) of caffeine)
Trial: 14634576
Drug: Presumptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumptive treatment with azithromycin, cefixime, and metronidazole
Trial: 14634576
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for Trichomonas vaginalis
Trial: 9008498
Drug: Tolcapone 50
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 50 mg tid
Trial: 9008498
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg tid
Trial: 9008498
Drug: Tolcapone 400
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 400 mg tid
Trial: 3297181
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three dosage regimens (RR, SR, SR-F)
Trial: 23975663
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (oxaliplatin/FU) - Arm B
Trial: 23975663
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction chemotherapy - Arm A
Trial: 21439823
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m² IV on days 1, 8, 15, 22, and 29) and uracil-tegafur (300 mg/m² TID from days 1-28) with folinic acid (90 mg QD)
Trial: 11743288
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose conformal radiation therapy (77.4 Gy delivered to the prostate)
Trial: 9521253
Drug: L-deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-deprenyl (10 mg daily)
Trial: 2913547
Drug: Cefuroxime or
RxNorm normalized name: cefuroxime Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime or ceftriaxone therapy
Trial: 27928721
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg selenium supplements as tablet (n = 30)
Trial: 17267841
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment at 20-24 weeks
Trial: 15541252
Drug: Eptifibatide (glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (glycoprotein IIb/IIIa platelet receptor inhibitor) for 24 hours
Trial: 11941231
Drug: Amukine 0.06%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amukine 0.06% solution
Trial: 11941231
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine (Bétadine) 5% solution
Trial: 10230996
Drug: Antiparkinsonian medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparkinsonian medications in PD-F patients
Trial: 14652
Drug: Carpipramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carpipramine (3 X 100 mg daily for 43 days)
Trial: 30977382
Drug: Lycra® gauntlets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycra® gauntlets for eight hours daily for eight weeks, plus usual rehabilitation (n=27)
Trial: 23443830
Drug: basic combination
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic combination (white bread, milk, spreads, juice, ice-cream)
Trial: 11773207
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone + Testosterone (GH + T)
Trial: 11773207
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) + HRT
Trial: 9561680
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment (more prevalent in CyA-treated patients)
Trial: 2722224
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone (200 mg/day for 1 week)
Trial: 55717
Drug: Diazoxide 5
RxNorm normalized name: diazoxide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide 5 mg/kg/day for 7 days with insulin
Trial: 55717
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with insulin
Trial: 25298894
Drug: Topical menthol
RxNorm normalized name: menthol Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical menthol (Biofreeze)
Trial: 25298894
Drug: Placebo (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gel with a menthol scent)
Trial: 10411810
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy in addition to antimicrobial agents
Trial: 10411810
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy alone
Trial: 3886395
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg plus codeine 30 mg
Trial: 25335944
Drug: Proactive +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive + 4 weeks of medication (Counselor‐initiated intervention)
Trial: 25335944
Drug: Reactive +
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive + 2 weeks of medication (Participant‐initiated intervention)
Trial: 15248204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone)
Trial: 12587686
Drug: Bromelain 200
RxNorm normalized name: Bromelain
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain 200 mg per day
Trial: 12587686
Drug: Bromelain 400
RxNorm normalized name: ARNICA MONTANA FLOWER 50 mg / STEM BROMELAIN 400 mg / SODIUM ASCORBATE 120 mg / HESPERIDIN METHYLCHALCONE 25 mg / RUTIN 50 mg / DIOSMIN 200 mg / HESPERIDIN 25 mg / ZINC PICOLINATE 10 mg ORAL TABLET [Bruselix Bruising]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain 400 mg per day
Trial: 9535138
Drug: Newer blood-pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer blood-pressure-lowering drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists)
Trial: 9535138
Drug: Newer blood-pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer blood-pressure-lowering treatments
Trial: 9535138
Drug: Older classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older classes of blood-pressure-lowering drugs
Trial: 7640499
Drug: Lappaconitine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lappaconitine 4 ml
Trial: 7640499
Drug: Lappaconitine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lappaconitine 8 ml
Trial: 7640499
Drug: Lappaconitine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lappaconitine 12 ml
Trial: 7640499
Drug: 0.9% NS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NS 6 ml (Control)
Trial: 7640499
Drug: Morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2 mg (Control)
Trial: 1325010
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of lisinopril and sustained release verapamil (group III)
Trial: 1325010
Drug: Lisinopril alone
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril alone (group I)
Trial: 26963073
Drug: Standard nonoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nonoperative treatment
Trial: 21699645
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg/day)
Trial: 17671533
Drug: Postoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative chemoradiation (surgery followed by radiation therapy at 50Gy/5 weeks, 2Gy/fraction, 5 days/week) plus chemotherapy (Leucovorin 300mg/m2 followed by 5-FU 350mg/m2)
Trial: 17671533
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (46Gy/4.5 weeks, 2Gy/fraction, 5 days/week) followed by surgery +/- postoperative chemotherapy
Trial: 11202417
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg gossypol
Trial: 11202417
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg gossypol
Trial: 2454358
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg b.i.d.)
Trial: 29648642
Drug: Frontal cerebral
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal cerebral thermal therapy (maintained at 14‐16°C)
Trial: 24745696
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg, every 3 weeks for 1 year
Trial: 17656661
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intraarterial approach to recanalization
Trial: 11919227
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5-FU-based)
Trial: 3066856
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy combined with CCNU chemotherapy (100 mg/sq m every 6-8 weeks)
Trial: 30371518
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (neuroma excision and burying into muscle)
Trial: 27922029
Drug: Eluxadoline 75
RxNorm normalized name: eluxadoline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline 75 mg BID
Trial: 27922029
Drug: Eluxadoline 100
RxNorm normalized name: eluxadoline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline 100 mg BID
Trial: 26547229
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without treatment for edema
Trial: 16784956
Drug: DHEA (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100-400 mg/d)
Trial: 9420016
Drug: Combination 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination 5‐FU plus leucovorin (LV)
Trial: 9420016
Drug: Monthly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly schedule of 5‐FU/LV (200 mg/m2)
Trial: 9420016
Drug: Weekly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly schedule of 5‐FU/LV (high-dose LV)
Trial: 9420016
Drug: Racemic commercial
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic commercial formulation of LV
Trial: 9420016
Drug: Sequential methotrexate/5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential methotrexate/5‐FU
Trial: 9420016
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion schedules of 5‐FU
Trial: 8305958
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) at a dose of 400 mg/kg
Trial: 31894236
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone enanthate/week
Trial: 22711752
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg b.i.d.
Trial: 22863658
Drug: DTaP-IPV-Hep B-PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-Hep B-PRP-T vaccine
Trial: 22863658
Drug: Licensed hexavalent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed hexavalent control vaccine (Infanrix™ hexa)
Trial: 19423470
Drug: Sequential intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily
Trial: 19423470
Drug: i.v. ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ceftriaxone 2 g once daily plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily
Trial: 19423470
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (moxifloxacin and ceftriaxone/metronidazole)
Trial: 18270944
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine (15 mg) plus 75 mg of hyperbaric lidocaine 5%
Trial: 18270944
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline plus 75 mg of hyperbaric lidocaine 5%
Trial: 11552922
Drug: rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 10 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Trial: 11552922
Drug: rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Trial: 11552922
Drug: rabeprazole 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 40 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Trial: 7946364
Drug: Rocuronium 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 600 micrograms/kg intubation dose
Trial: 7946364
Drug: Maintenance doses
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance doses of rocuronium
Trial: 21663949
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Trial: 23332608
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention (cognitive behavioral therapy, psychotropic medication or both)
Trial: 18926434
Drug: Conivaptan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan (20 mg loading dose followed by 2 successive 24-hour continuous infusions of 40, 80, or 120 mg/d)
Trial: 8973993
Drug: Dextroamphetamine 5
RxNorm normalized name: dextroamphetamine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 5 mg
Trial: 8973993
Drug: Dextroamphetamine 10
RxNorm normalized name: dextroamphetamine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 10 mg
Trial: 9617982
Drug: Dextroamphetamine 20
RxNorm normalized name: dextroamphetamine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 20 mg
Trial: 1456384
Drug: New slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New slow-release preparation of valproic acid (SR-VPA)
Trial: 1456384
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation of valproic acid (C-VPA)
Trial: 29630570
Drug: Controlled Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Active Motion (CAM) therapy
Trial: 29630570
Drug: Continuous Passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Passive Motion (CPM) therapy
Trial: 26352863
Drug: Melatonin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1 or 3 mg nightly)
Trial: 25130678
Drug: Atorvastatin (20mg/d)
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20mg/d)
Trial: 22787067
Drug: Full-dose polycap
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose polycap (plus K(+) supplementation)
Trial: 22787067
Drug: Low-dose polycap
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose polycap